Literature DB >> 20355236

Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer.

Pieter C Dagnelie1, Susanne Leij-Halfwerk.   

Abstract

This review provides an overview of the current state of the art of magnetic resonance spectroscopy (MRS) in in vivo investigations of diffuse liver disease. So far, MRS of the human liver in vivo has mainly been used as a research tool rather than a clinical tool. The liver is particularly suitable for static and dynamic metabolic studies due to its high metabolic activity. Furthermore, its relatively superficial position allows excellent MRS localization, while its large volume allows detection of signals with relatively low intensity. This review describes the application of MRS to study the metabolic consequences of different conditions including diffuse and chronic liver diseases, congenital diseases, diabetes, and the presence of a distant malignancy on hepatic metabolism. In addition, future prospects of MRS are discussed. It is anticipated that future technical developments such as clinical MRS magnets with higher field strength (3 T) and improved delineation of multi-component signals such as phosphomonoester and phosphodiester using proton decoupling, especially if combined with price reductions for stable isotope tracers, will lead to intensified research into metabolic syndrome, cardiovascular disease, hepato-biliary diseases, as well as non-metastatic liver metabolism in patients with a distant malignant tumor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20355236      PMCID: PMC2848366          DOI: 10.3748/wjg.v16.i13.1577

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Etiology and functional status of liver cirrhosis by 31P MR spectroscopy.

Authors:  Monika Dezortova; Pavel Taimr; Antonin Skoch; Julius Spicak; Milan Hajek
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  1H MRS of liver and brain in a patient with AL amyloidosis.

Authors:  W Roser; K W Stock
Journal:  Magn Reson Imaging       Date:  1997       Impact factor: 2.546

3.  31P magnetic resonance spectroscopy of the liver in HELLP syndrome.

Authors:  L A Magee; R M Dixon; G J Kemp; C W Redman; P Styles
Journal:  Br J Obstet Gynaecol       Date:  1999-06

4.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Douglas Befroy; Michael Lehrke; Rosa E Hendler; Gerald I Shulman
Journal:  Diabetes       Date:  2005-03       Impact factor: 9.461

5.  Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes.

Authors:  Martin Krssak; Attila Brehm; Elisabeth Bernroider; Christian Anderwald; Peter Nowotny; Chiara Dalla Man; Claudio Cobelli; Gary W Cline; Gerald I Shulman; Werner Waldhäusl; Michael Roden
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

6.  Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation.

Authors:  E Tarasów; A Wiercińska-Drapało; J Jaroszewicz; L Siergiejczyk; A Orzechowska-Bobkiewicz; D Prokopowicz; J Walecki
Journal:  Acta Radiol       Date:  2004-12       Impact factor: 1.990

7.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer.

Authors:  L E Gerweck; K Seetharaman
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  Effect of ethanol and fructose on liver metabolism: a dynamic 31Phosphorus magnetic resonance spectroscopy study in normal volunteers.

Authors:  C Boesch; C Elsing; H Wegmüller; J Felblinger; P Vock; J Reichen
Journal:  Magn Reson Imaging       Date:  1997       Impact factor: 2.546

9.  Non-T1-weighted 31P chemical shift imaging of the human liver.

Authors:  P E Sijens; P Van Dijk; P C Dagnelie; M Oudkerk
Journal:  Magn Reson Imaging       Date:  1995       Impact factor: 2.546

10.  In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver.

Authors:  S D Taylor-Robinson; J Sargentoni; J D Bell; N Saeed; K K Changani; B R Davidson; K Rolles; A K Burroughs; H J Hodgson; C S Foster; I J Cox
Journal:  Liver       Date:  1997-08
View more
  12 in total

1.  Liver magnetic resonance imaging: State of the art.

Authors:  Paul E Sijens
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities.

Authors:  Hui Dong; Fu'er Lu; Nan Wang; Xin Zou; Jingjing Rao
Journal:  Front Med       Date:  2011-10-02       Impact factor: 4.592

3.  Quantification of choline concentration following liver cell apoptosis using 1H magnetic resonance spectroscopy.

Authors:  Zhi-Wei Shen; Zhen Cao; Ke-Zeng You; Zhong-Xian Yang; Ye-Yu Xiao; Xiao-Fang Cheng; Yao-Wen Chen; Ren-Hua Wu
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

4.  Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content.

Authors:  Bo Zhang; Fang Ding; Tian Chen; Liang-Hua Xia; Juan Qian; Guo-Yi Lv
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 5.  In vivo imaging techniques: a new era for histochemical analysis.

Authors:  A Busato; P Fumene Feruglio; P P Parnigotto; P Marzola; A Sbarbati
Journal:  Eur J Histochem       Date:  2016-11-28       Impact factor: 3.188

Review 6.  Health outcomes of a high fructose intake: the importance of physical activity.

Authors:  Luc Tappy; Robin Rosset
Journal:  J Physiol       Date:  2019-06-09       Impact factor: 5.182

Review 7.  Assessment of Malnutrition, Sarcopenia and Frailty in Patients with Cirrhosis: Which Tools Should We Use in Clinical Practice?

Authors:  Benjamin Buchard; Yves Boirie; Lucie Cassagnes; Géraldine Lamblin; A Coilly; Armando Abergel
Journal:  Nutrients       Date:  2020-01-09       Impact factor: 5.717

8.  Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.

Authors:  Y-C Shen; D-L Ou; C Hsu; K-L Lin; C-Y Chang; C-Y Lin; S-H Liu; A-L Cheng
Journal:  Br J Cancer       Date:  2012-12-20       Impact factor: 7.640

Review 9.  Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine.

Authors:  Liang Wang
Journal:  Hepat Med       Date:  2010-08-17

10.  Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection.

Authors:  Jadegoud Yaligar; Wei Wei Teoh; Rashidah Othman; Sanjay Kumar Verma; Beng Hooi Phang; Swee Shean Lee; Who Whong Wang; Han Chong Toh; Venkatesh Gopalan; Kanaga Sabapathy; S Sendhil Velan
Journal:  Sci Rep       Date:  2016-02-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.